Fuente: FierceBiotech Royalty Pharma has made another play in the autoimmune space, this time crowning Johnson & Johnson as the beneficiary. Royalty and J&J have agreed to co-fund the development of a chronic autoimmune disease treatment, with Royalty pitching in $500 million over the next two years.